FY2024 Earnings Estimate for PLX Issued By HC Wainwright

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities research analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Protalix BioTherapeutics in a report released on Monday, February 3rd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of $0.01 for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2024 earnings at $0.06 EPS and FY2025 earnings at $0.19 EPS.

Separately, StockNews.com downgraded shares of Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday.

Protalix BioTherapeutics Price Performance

Protalix BioTherapeutics stock opened at $2.67 on Wednesday. The business has a 50 day moving average of $2.01 and a 200-day moving average of $1.43. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $2.71. The company has a market capitalization of $196.59 million, a P/E ratio of -20.54 and a beta of 0.75.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PLX. Squarepoint Ops LLC raised its position in Protalix BioTherapeutics by 673.3% in the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock valued at $161,000 after buying an additional 119,949 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Protalix BioTherapeutics during the second quarter valued at about $67,000. Virtu Financial LLC purchased a new position in Protalix BioTherapeutics during the third quarter worth about $44,000. Sanctuary Advisors LLC bought a new stake in Protalix BioTherapeutics in the 3rd quarter worth about $38,000. Finally, XTX Topco Ltd purchased a new stake in Protalix BioTherapeutics in the 3rd quarter valued at about $36,000. 16.53% of the stock is owned by institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.